| Bioactivity | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. |
| In Vivo | GSK360A (30 mg/kg i.g.) 在已建立的心室功能障碍模型中改善长期心室功能、重塑和血管分布[1]。 Animal Model: |
| Name | GSK360A |
| CAS | 931399-19-8 |
| Formula | C17H17FN2O5 |
| Molar Mass | 348.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bao W, et, al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. |